Yes, kids can get ALS, but it is extraordinarily rare: fewer than 1 in 1 million children under 18 develop amyotrophic lateral sclerosis each year, and only about 1 to 2 percent of all ALS cases begin before age 25. When ALS does strike a child, it is almost always the inherited juvenile form, driven by a single gene mutation such as FUS, SETX, or SOD1, rather than the sporadic disease that affects adults in their 60s. The disease process is the same either way: motor neurons in the spinal cord and brainstem die, muscles weaken, and strength is lost progressively. Recognizing that a child with ALS exists at all matters, because the odds are low but not zero.
The mechanism: why motor neurons die in a child
ALS is a disease of the upper and lower motor neurons, the nerve cells that carry movement commands from the brain to muscle. In every form of the disease, these cells degenerate and die, and the muscle fibers they control shrink and stop working. What differs in children is the trigger.
In roughly 90 percent of adult ALS cases, no single cause is identified, and the disease appears to arise from a mix of genetic risk and environmental exposure over decades. In juvenile ALS, the reverse is true. A pathogenic variant in one gene is found in most pediatric cases, and that variant is usually inherited from a parent or arises as a new mutation in the child.
The FUS gene is the most common driver of juvenile ALS. FUS codes for a protein that normally shuttles between the nucleus and cytoplasm and helps package RNA. When mutated, the protein clumps into abnormal aggregates inside motor neurons, and the cell's RNA processing breaks down. The SETX gene causes a form that often begins in the first decade of life. SOD1 mutations produce a form that can start in adolescence or early adulthood and tends to run faster than the adult sporadic disease. ALS2 mutations cause a slowly progressive juvenile form that can look like spastic paraplegia before weakness spreads.
In plain terms: in a child, ALS is usually a single broken gene doing direct damage to motor neurons, not the slow accumulation of damage that drives most adult cases.
The cell death itself follows a common pathway. Motor neurons lose their ability to clear damaged proteins, mitochondria fail, and the axon that reaches from the spinal cord to the muscle degenerates. This is why weakness in juvenile ALS often begins in the legs or the hands and spreads, rather than starting with the bulbar muscles that control speech and swallowing.
How rare is ALS in children? The numbers
The incidence figures are important because they set realistic expectations. ALS overall affects about 1.5 to 2.5 people per 100,000 each year in the United States, and the median age at diagnosis is 58 to 63. Cases beginning before age 18 are so uncommon that most neurologists will never see one.
| Age group | Share of all ALS cases | Approximate annual incidence | Usual genetic pattern |
|---|---|---|---|
| Under 18 (juvenile ALS) | Under 1 percent | Fewer than 1 per 1 million children | Inherited in most cases |
| 18 to 25 (young-onset) | About 1 to 2 percent | Roughly 0.1 to 0.3 per 100,000 | Inherited in a minority |
| 26 to 45 | About 10 percent | Roughly 0.5 to 1 per 100,000 | Mostly sporadic |
| Over 45 | About 88 percent | 3 to 5 per 100,000 | Mostly sporadic |
The numbers in the table reconcile as follows: the under-18 and 18-to-25 groups together account for no more than about 3 percent of all cases, which is why the over-45 share sits near 88 percent and the 26-to-45 share near 10 percent. These are estimates, and different registries report ranges rather than single values.
The rarity has a practical consequence. A general pediatrician may practice for 30 years and never encounter a confirmed case. That does not mean the disease is impossible, but it does mean that a diagnosis of ALS in a child is usually made at a specialist center after other, far more common conditions have been excluded.
What juvenile ALS looks like: symptoms and the diagnostic path
The first symptom is usually weakness that does not improve. In young children, that can mean tripping more often, difficulty climbing stairs, or a hand that drops objects. In older children and teenagers, it may be a foot that drags, a wrist that feels weak, or muscle wasting visible in the hands.
The warning signs that should prompt urgent neurological evaluation are a specific list:
- Progressive weakness in one limb that spreads over weeks to months
- Visible muscle wasting, especially in the hands or between the fingers
- Muscle twitching (fasciculations) that persists at rest
- Slurred speech or difficulty swallowing that is not explained by another cause
- Stiffness or spasticity in the legs alongside weakness
- A family history of ALS, motor neuron disease, or unexplained progressive weakness
A red flag that matters in children is a combination of upper motor neuron signs and lower motor neuron signs in the same limb. Upper motor neuron signs include increased reflexes and spasticity. Lower motor neuron signs include weakness, wasting, and twitching. When both appear together, motor neuron disease moves up the differential.
Diagnosis is a process of exclusion plus confirmation. A neurologist will order an electromyogram and nerve conduction study, which show whether the electrical signal from nerve to muscle is failing. Genetic testing for FUS, SETX, SOD1, ALS2, and related genes is now standard in pediatric cases, because a positive result both confirms the diagnosis and informs family counseling. MRI of the brain and spine rules out structural causes. Blood tests exclude mimics such as inflammatory neuropathy, which is treatable and far more common.
The timeline from first symptom to diagnosis is often long in children, because the disease is so rare that it is not considered early.
Timeline: from first symptom to diagnosis in juvenile ALS
| Stage | Typical timing | What happens |
|---|---|---|
| First symptom | Week 0 | Weakness, tripping, or hand clumsiness noticed by a parent or teacher |
| Initial medical visit | Weeks 1 to 8 | Pediatrician evaluates, often suspects a sports injury or growth issue |
| Specialist referral | Months 1 to 6 | Neurology referral after weakness persists or spreads |
| Electrical testing | Months 2 to 9 | Electromyogram and nerve conduction study show motor neuron damage |
| Genetic testing | Months 3 to 12 | Panel identifies a mutation in most juvenile cases |
| Confirmed diagnosis | Months 4 to 18 | Diagnosis made after mimics are excluded |
The key figure in this table is the 4-to-18-month window to diagnosis. It is longer than the adult window, which typically runs 9 to 12 months from symptom onset, because pediatricians rightly look for common causes first. The trade-off is that genetic testing, when the family history is positive, can shorten the path considerably.
Why the diagnosis is often missed or delayed
The most common misconception about ALS in children is that a diagnosis in a child means the same prognosis as in an adult. It does not.
Juvenile ALS is genetically heterogeneous, and survival varies widely by mutation. The FUS form can progress rapidly, with survival measured in months to a few years from onset in some reports. The SETX form and the ALS2 form are slower, and some children live for a decade or more. Adult sporadic ALS has a median survival of 2 to 5 years from symptom onset, so the pediatric range is broader in both directions.
A second misconception is that ALS never happens before adulthood because the disease is "wear and tear" on aging neurons. The genetic evidence contradicts this. The mutations that cause juvenile ALS are present from conception, and the disease process begins when the motor neurons can no longer compensate for the mutant protein. Age modifies the course, but it does not create the disease.
A third misconception concerns misdiagnosis in the other direction. Some children diagnosed with a progressive motor neuron disease later turn out to have a treatable mimic, such as chronic inflammatory demyelinating polyneuropathy or a spinal muscular atrophy variant. This is why repeat evaluations at a specialist center matter.
Juvenile ALS versus adult ALS versus treatable mimics
The comparison that matters clinically is between juvenile ALS, adult ALS, and the conditions that imitate them. The differences guide both testing and expectations.
| Feature | Juvenile ALS | Adult sporadic ALS | Treatable mimic (e.g., inflammatory neuropathy) |
|---|---|---|---|
| Typical age at onset | Under 18 | 58 to 63 (median) | Any age |
| Genetic cause identified | Most cases | About 10 percent | Not genetic |
| Speed of progression | Variable, often faster in FUS | Median survival 2 to 5 years | Improves with treatment |
| Response to immunotherapy | None established | None established | Often substantial |
| Key diagnostic test | Genetic panel | Clinical plus electrical testing | Nerve conduction study, spinal fluid |
The practical takeaway from this table is that a child with progressive weakness should receive both genetic testing and a careful search for treatable mimics before anyone accepts a motor neuron disease diagnosis. The two paths run in parallel, not in sequence.
What to actually do if you suspect ALS in a child
The concrete actions are ordered by urgency, and none of them is watchful waiting.
First, document the weakness. Take dated videos of the child walking, climbing stairs, and gripping objects. A record of change over weeks is more useful to a neurologist than a single examination.
Second, request a pediatric neurology referral, not a general neurology referral, when the child is under 18. Pediatric neuromuscular specialists see the relevant differential more often.
Third, ask specifically for genetic testing for motor neuron disease genes if there is any family history of ALS, and ask about the FUS, SETX, SOD1, and ALS2 genes by name. Insurance coverage for these panels has improved, and a positive result changes counseling for siblings.
Fourth, ask whether the workup has excluded treatable mimics, including inflammatory neuropathy and spinal muscular atrophy. A trial of immunotherapy is sometimes appropriate while genetic results are pending.
Fifth, connect with a multidisciplinary team that includes a pulmonologist, a speech therapist, and a dietitian early, before breathing or swallowing problems appear. In juvenile ALS, proactive respiratory monitoring with regular breathing tests can extend the period of independent living.
What not to do is equally specific. Do not accept a diagnosis of "growing pains" or a sports injury without a follow-up examination in 4 to 6 weeks if weakness persists. Do not delay genetic testing to save cost if a family history exists. Do not start unproven supplements marketed for ALS.
Treatment reality and honest limits
No drug reverses ALS in children or adults. The approved adult medications, riluzole and edaravone, have been studied almost entirely in adults, and pediatric evidence is limited to case reports. Their use in children is off-label and decided case by case at specialist centers, with the rationale that the underlying motor neuron death is similar.
For children with a known FUS mutation, experimental approaches targeting the mutant gene, including antisense oligonucleotide therapy, are in early clinical development. These are promising but unproven, and families should understand that "in trials" does not mean "effective."
The honest limit is this: the rarity of juvenile ALS means that no large pediatric trial exists, and every treatment decision is extrapolated from adult data or from individual experience. The best available care is a specialist multidisciplinary team, early respiratory support, and genetic counseling for the family. That is a modest toolkit, but it is the accurate one.
The final point a parent should hold onto is the one the numbers support. ALS in a child is real, it is genetically driven in most cases, and it is rare enough that a single case is worth a specialist referral rather than reassurance alone.